Aeterna Zentaris CEO David J. Mazzo And Chief Business Officer Ellen McDonald: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Execs discuss their partnering strategy, expanding into Asia and the potential of being acquired.
You may also be interested in...
Aeterna Zentaris CEO David J. Mazzo And Chief Business Officer Ellen McDonald: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Execs discuss how their BPH treatment will take on products such as Pfizer’s Detrol and GlaxoSmithKline’s Avodart, as well as how their development strategy differs from other biopharmas.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.